<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROMETHAZINE WITH CODEINE  - promethazine hydrochloride and codeine phosphate liquid </strong><br>Apotheca, Inc.<br></p></div>
<h1>PROMETHAZINE HCI AND CODEINE PHOSPHATE
6.25MG/10MG PER 5ML
RX ONLY</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION </h1>Each 5 ml (one teaspoonful), for oral administration contains: Promethazine hydrochloride 6.25 mg; codeine phosphate 10 mg. Alcohol 7%<br><span class="Italics">Inactive Ingredients: </span>Artificial raspberry flavor, ascorbic acid, citric acid anhydrous, D and C Red #33, dehydrated alcohol, edetate<br>disodium, FD and C Blue #1, glycerin, liquid sugar, methylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate<br>dihydrate and sodium propionate.<span class="Italics">(for Mortin Grove Pharmaceuticals)</span><br><span class="Italics">Inactive ingredients</span>: Artificial and natural boysenberry flavor, citric acid, D and C Red #33, FD and C Blue #1, FD and C Yellow #6,<br>glycerin, saccharin sodium, sodium benzoate, sodium citrate, sodium propionate, sucrose and purified water.<span class="Italics">(for HI Tech Pharmacal Co.)</span><br>Codeine is one of the naturally occurring phenanthrene alkaloids of opium derived from the opium poppy; it is classified<br>pharmacologically as a narcotic analgesic. Codeine phosphate may be chemically designated as 7,8-Didehydro-4,5a-epoxy-3-<br>methoxy-17-methylmorphinan-6a- ol phosphate (1:1)(salt) hemihydrate.<br>The phosphate salt of codeine occurs as white, needle-shaped crystals or white crystalline powder. Codeine phosphate is freely soluble<br>in water and slightly soluble in alcohol. It has a molecular weight of 406.37, a molecular formula of C18H21NO3•H3PO4•½H2O, and<br>the following structural formula:<br><div class="Figure"><img alt="image of structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47d4eb4f-6dd4-44b9-aea1-19c4bfc1d425&amp;name=prohydro-01.jpg"></div>
<br><br><br><br>Promethazine hydrochloride, a phenothiazine derivative, is chemically designated as (±)-10-[2-(Dimethylamino)propyl] phenothiazine<br>monohydrochloride.<br>Promethazine hydrochloride occurs as a white to <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> yellow, practically odorless, crystalline powder which slowly oxidizes and turns<br>blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. It has a molecular weight of 320.88, a molecular<br>formula of C17H20N2S•HCl, and the following structural formula:<br><div class="Figure"><img alt="image of formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47d4eb4f-6dd4-44b9-aea1-19c4bfc1d425&amp;name=prohydro-02.jpg"></div>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<span class="Bold">Codeine</span><p class="First">Narcotic analgesics, including codeine, exert their primary 
effects on the central nervous system and gastrointestinal tract. The analgesic 
effects of codeine are due to its central action; however, the precise sites of 
action have not been determined, and the mechanisms involved appear to be quite 
complex. Codeine resembles morphine both structurally and pharmacologically, but 
its actions at the doses of codeine used therapeutically are milder, with less 
sedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and gastrointestinal, urinary, and pupillary 
effects. Codeine produces an increase in biliary tract pressure, but less than 
morphine or meperidine. Codeine is less constipating than morphine.</p>
<p>Codeine has good antitussive activity, although less than that of morphine at 
equal doses. It is used in preference to morphine, because side effects are 
infrequent at the usual antitussive dose of codeine.</p>
<p>Codeine in oral therapeutic dosage does not usually exert major effects on 
the cardiovascular system.</p>
<p>Narcotic analgesics may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by stimulating the 
chemoreceptor trigger zone (CTZ); however, they also depress the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> 
center, so that subsequent doses are unlikely to produce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> is 
minimal after usual oral doses of codeine.</p>
<p>Narcotic analgesics cause histamine release, which appears to be responsible 
for <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">wheals</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> sometimes seen at the site of injection on parenteral 
administration. Histamine release may also produce dilation of cutaneous blood 
vessels, with resultant <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the face and neck, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and 
<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p>Codeine and its salts are well absorbed following both oral and parenteral 
administration. Codeine is about 2/3 as effective orally as parenterally. 
Codeine is metabolized primarily in the liver by enzymes of the endoplasmic 
reticulum, where it undergoes O-demethylation, N-demethylation, and partial 
conjugation with glucuronic acid. The drug is excreted primarily in the urine, 
largely as inactive metabolites and small amounts of free and conjugated 
morphine. Negligible amounts of codeine and its metabolites are found in the 
feces.</p>
<p>Following oral or subcutaneous administration of codeine, the onset of 
<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> occurs within 15 to 30 minutes and lasts for four to six hours.</p>
<p>The <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>-depressing action, in animal studies, was observed to occur 15 
minutes after oral administration of codeine, peak action at 45 to 60 minutes 
after ingestion. The duration of action, which is dose-dependent, usually did 
not exceed 3 hours.</p>
<a href="#section-"></a><span class="Bold">Promethazine</span><p>Promethazine is a phenothiazine derivative which differs 
structurally from the antipsychotic phenothiazines by the presence of a branched 
side chain and no ring substitution. It is thought that this configuration is 
responsible for its relative lack (1/10 that of chlorpromazine) of dopamine 
antagonist properties.</p>
<p>Promethazine is an H<span class="Sub">1</span> receptor blocking agent. In 
addition to its antihistaminic action, it provides clinically useful sedative 
and antiemetic effects.</p>
<p>Promethazine is well absorbed from the gastrointestinal tract. Clinical 
effects are apparent within 20 minutes after oral administration and generally 
last four to six hours, although they may persist as long as 12 hours. 
Promethazine is metabolized by the liver to a variety of compounds; the 
sulfoxides of promethazine and N-demethylpromethazine are the predominant 
metabolites appearing in the urine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE </h1>Promethazine with codeine syrup is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughs</span> 
and upper respiratory symptoms associated with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">The combination of promethazine hydrochloride and codeine 
phosphate is contraindicated in pediatric patients less than 6 years of age, 
because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this age 
population.</p>
<p>Codeine is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the 
drug.</p>
<p>Promethazine is contraindicated in <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> states, and in individuals known 
to be hypersensitive or to have had an idiosyncratic reaction to promethazine or 
to other phenothiazines.</p>
<p>Antihistamines and codeine are both contraindicated for use in the treatment 
of lower respiratory tract symptoms, including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Warning">
<a name="section-5"></a><p></p>
<h1>WARNING:</h1>
<a href="#section-"></a><p class="First"><span class="Bold">The combination of promethazine 
hydrochloride and codeine phosphate is contraindicated in pediatric patients 
less than 6 years of age. Concomitant administration of promethazine products 
with other respiratory depressants has an association with respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric patients.</span></p>
<p><span class="Bold">Postmarketing cases of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, including 
fatalities, have been reported with use of promethazine hydrochloride in 
pediatric patients less than 2 years of age. A wide range of weight-based doses 
of promethazine hydrochloride have resulted in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these 
patients.</span></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Codeine</span></p>
<p>Dosage of codeine <span class="Italics">SHOULD NOT BE INCREASED</span> if <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> fails to 
respond; an unresponsive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be reevaluated in 5 days or sooner for 
possible underlying pathology, such as foreign body or lower respiratory tract 
disease.</p>
<p>Codeine may cause or aggravate <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> leading to arrest, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred with 
the use of codeine antitussives in young children, particularly in the 
under-one-year infants whose ability to deactivate the drug is not fully 
developed.</p>
<p>Administration of codeine may be accompanied by histamine release and should 
be used with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> children.</p>
<a href="#section-"></a><a href="#section-"></a><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> And <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>:<p>The respiratory-depressant effects of narcotic analgesics and 
their capacity to elevate cerebrospinal fluid pressure may be markedly 
exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions or a 
pre-existing increase in intracranial pressure. Narcotics may produce adverse 
reactions which may obscure the clinical course of patients with head 
injuries.</p>
<a href="#section-"></a><a href="#section-"></a><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> And Other Respiratory Conditions:<p>Narcotic analgesics or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> suppressants, including codeine, 
should not be used in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients <span class="Bold">(see CONTRAINDICATIONS).</span> 
Nor should they be used in acute febrile illness associated with productive 
<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or in <span class="product-label-link" type="condition" conceptid="4063381" conceptname="Chronic disease of respiratory system">chronic respiratory disease</span> where interference with ability to clear 
the tracheobronchial tree of secretions would have a deleterious effect on the 
patient's respiratory function.</p>
<a href="#section-"></a><a href="#section-"></a>Hypotensive Effect:<p>Codeine may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory 
patients</p>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5.1"></a><p></p>
<h2>Promethazine:</h2>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS Depression</span> –</span><p class="First">Promethazine may impair the mental and/or physical abilities 
required for the performance of potentially hazardous tasks, such as driving a 
vehicle or operating machinery. The impairment may be amplified by concomitant 
use of other central-nervous-system depressants such as alcohol, 
sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, 
general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, 
such agents should either be eliminated or given in reduced dosage in the 
presence of promethazine HCl <span class="Bold">(see PRECAUTIONS 
- Information For Patients</span><span class="Bold">and Drug 
Interactions).</span></p>
<a href="http://"></a><a href="http://"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span> –</span><p>Promethazine may lead to potentially fatal respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>Use of promethazine in patients with compromised respiratory function (e.g., 
<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>) should be avoided.</p>
<a href="http://"></a><a href="http://"></a><span class="Bold">Lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Threshold –</span><p>Promethazine may lower <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. It should be used with 
caution in persons with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or in persons who are using 
concomitant medications, such as narcotics or local anesthetics, which may also 
affect <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</p>
<a href="http://"></a><a href="http://"></a><span class="Bold">Bone-<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Marrow Depression</span> –</span><p>Promethazine should be used with caution in patients with bone 
<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported, usually 
when promethazine HCl has been used in association with other known marrow-toxic 
agents.</p>
<a href="http://"></a><a href="http://"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> –</span><p>A potentially fatal symptom complex sometimes referred to as 
<span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with 
promethazine HCl alone or in combination with antipsychotic drugs. Clinical 
manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status 
and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In 
arriving at a diagnosis, it is important to identify cases where the clinical 
presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and 
symptoms (EPS). Other important considerations in the differential diagnosis 
include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary 
central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of 
promethazine HCl, antipsychotic drugs, if any, and other drugs not essential to 
concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, 
and 3) treatment of any concomitant serious medical problems for which specific 
treatments are available. There is no general agreement about specific 
pharmacological treatment regimens for uncomplicated NMS.</p>
<p>Since recurrences of NMS have been reported with phenothiazines, the 
reintroduction of promethazine HCl should be carefully considered</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5.2"></a><p></p>
<h2>Use In Pediatric Patients</h2>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride 
and codeine phosphate is contraindicated in pediatric patients less than 6 years 
of age. Concomitant administration of promethazine products with other 
respiratory depressants has an association with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and 
sometimes <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in pediatric patients. The association does not directly relate 
to individualized weight-based dosing, which might otherwise permit safe 
administration.</span></p>
<p>Excessively large dosages of antihistamines, including promethazine 
hydrochloride, in pediatric patients may cause <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> <span class="Bold">(see OVERDOSAGE).</span> 
<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> have occurred with therapeutic doses and 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of promethazine hydrochloride in pediatric patients. In pediatric 
patients who are acutely ill associated with <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, there is an increased 
susceptibility to <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonias</span> with the use of promethazine HCl.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5.3"></a><p></p>
<h2>Other Considerations</h2>Administration of promethazine has been associated with reported cholestatic 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>Animal reproduction studies have not been conducted with the drug 
combination-promethazine and codeine. It is not known whether this drug 
combination can cause fetal harm when administered to a pregnant woman or can 
affect reproduction capacity. Promethazine hydrochloride and codeine phosphate 
should be given to a pregnant woman only if clearly needed.<div class="Section" data-sectionCode="42232-9">
<a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">Narcotic analgesics, including codeine, should be administered 
with caution and the initial dose reduced in patients with acute abdominal 
conditions, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, significant hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, 
<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, prostatic 
<span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, in patients with recent gastrointestinal or urinary tract surgery, 
and in the very young or elderly or debilitated patients.</p>
<p>Drugs having anticholinergic properties should be used with caution in 
patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, stenosing peptic 
<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, pyloroduodenal obstruction, and bladder-neck obstruction.</p>
<p>Promethazine should be used cautiously in persons with cardiovascular disease 
or with impairment of liver function.</p>
<a href="http://"></a><a href="http://"></a><span class="Bold">Ultra-Rapid Metabolizers of Codeine</span><p>Some individuals may be ultra-rapid metabolizers due to a 
specific CYP2D6*2x2 genotype. These individuals convert codeine into its active 
metabolite, morphine, more rapidly and completely than other people. This rapid 
conversion results in higher than expected serum morphine levels. Even at 
labeled dosage regimens, individuals who are ultra-rapid metabolizers may 
experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or shallow 
breathing.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated 
at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1–10% in 
Caucasians, 3% in African Americans, and 16–28% in North Africans, Ethiopians 
and Arabs. Data is not available for other ethnic groups.</p>
<p>When physicians prescribe codeine-containing drugs, they should choose the 
lowest effective dose for the shortest period of time and should inform their 
patients about these risks and the signs of morphine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span><span class="Bold"> (see PRECAUTIONS 
- Nursing Mothers).</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.2"></a><p></p>
<h2>Information For Patients:</h2>
<p class="First">Patients should be advised to measure promethazine with codeine 
syrup with an accurate measuring device. A household teaspoon is not an accurate 
measuring device and could lead to overdosage, especially when a half a teaspoon 
is measured. A pharmacist can recommend an appropriate measuring device and can 
provide instructions for measuring the correct dose.</p>
<p>Promethazine and codeine may cause marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or may impair the mental 
and/or physical abilities required for the performance of potentially hazardous 
tasks, such as driving a vehicle or operating machinery. Ambulatory patients 
should be told to avoid engaging in such activities until it is known that they 
do not become drowsy or dizzy from promethazine and codeine therapy. Pediatric 
patients should be supervised to avoid potential harm in bike riding or in other 
hazardous activities.</p>
<p>The concomitant use of alcohol or other central-nervous-system depressants, 
such as sedatives/hypnotics (including barbiturates), narcotics, narcotic 
analgesics, general anesthetics, tricyclic antidepressants, and tranquilizers 
may enhance impairment and should be avoided or their dosage reduced<span class="Bold"> (see WARNINGS-CNS 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and PRECAUTIONS-Drug 
Interactions).</span></p>
<p>Patients should be advised to report any <span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span>.</p>
<p>Avoid prolonged exposure to the sun.</p>
<p>Codeine, like other narcotic analgesics, may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> 
in some ambulatory patients. Patients should be cautioned accordingly.</p>
<p>Caution patients that some people have a variation in a liver enzyme and 
change codeine into morphine more rapidly and completely than other people. 
These people are ultra-rapid metabolizers and are more likely to have 
higher-than-normal levels of morphine in their blood after taking codeine which 
can result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or 
<span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. In most cases, it is unknown if someone is an ultra-rapid 
codeine metabolizer.</p>
<p>Nursing mothers taking codeine can also have higher morphine levels in their 
breast milk if they are ultra-rapid metabolizers. These higher levels of 
morphine in breast milk may lead to life-threatening or fatal side effects in 
nursing babies. Instruct nursing mothers to watch for signs of morphine toxicity 
in their infants including increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (more than usual), difficulty 
breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to 
talk to the baby's doctor immediately if they notice these signs and, if they 
cannot reach the doctor right away, to take the baby to an emergency room or 
call 911 (or local emergency services).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.3"></a><p></p>
<h2>Drug Interactions:</h2>
<span class="Bold">Codeine:</span><p class="First">In patients receiving MAO inhibitors, an initial small test dose 
is advisable to allow observation of any excessive narcotic effects or MAOI 
interaction.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Promethazine:<br><br></span><a href="#section-"></a><span class="Italics">CNS Depressants<br><br></span>Promethazine may increase, prolong, or intensify the sedative 
action of other central-nervous-system depressants, such as alcohol, 
sedatives/hypnotics (including barbiturates), narcotics, narcotic analgesics, 
general anesthetics, tricyclic antidepressants, and tranquilizers; therefore, 
such agents should be avoided or administered in reduced dosage to patients 
receiving promethazine HCl. When given concomitantly with promethazine, the dose 
of barbiturates should be reduced by at least one-half, and the dose of 
narcotics should be reduced by one-quarter to one-half. Dosage must be 
individualized. Excessive amounts of promethazine HCl relative to a narcotic may 
lead to <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and motor <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in the patient with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>; these 
symptoms usually disappear with adequate control of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.<br><br><a href="#section-"></a><span class="Italics">Epinephrine <br></span><p>Because of the potential for promethazine to reverse 
epinephrine's vasopressor effect, epinephrine should NOT be used to treat 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with promethazine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Italics">Anticholinergics <br></span><p>Concomitant use of other agents with anticholinergic properties 
should be undertaken with caution.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Italics">Monoamine Oxidase Inhibitors (MAOI) <br></span><p>Drug interactions, including an increased incidence of 
extrapyramidal effects, have been reported when some MAOI and phenothiazines are 
used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">Because narcotic analgesics may increase biliary tract pressure 
with resultant increases in plasma amylase or lipase levels, determination of 
these enzyme levels may be unreliable for 24 hours after a narcotic analgesic 
has been given.</p>
<p>The following laboratory tests may be affected in patients who are receiving 
therapy with promethazine hydrochloride.</p>
<a href="http://"></a><a href="http://"></a><span class="Italics">Pregnancy Tests:</span><p>Diagnostic pregnancy tests based on immunological reactions 
between HCG and anti-HCG may result in false-negative or false-positive 
interpretations.</p>
<a href="http://"></a><a href="http://"></a><span class="Italics">Glucose Tolerance Test:</span><p>An increase in blood glucose has been reported in patients 
receiving promethazine</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment Of Fertility:</h2>Long-term animal studies have not been performed to assess the carcinogenic 
potential of codeine or of promethazine, nor are there other animal or human 
data concerning carcinogenicity, mutagenicity, or impairment of fertility with 
these agents. Codeine has been reported to show no evidence of carcinogenicity 
or mutagenicity in a variety of test systems, including the micronucleus and 
sperm abnormality assays and the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  assay. 
Promethazine was nonmutagenic in the <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>  test 
system of Ames.</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.6"></a><p></p>
<h2>Pregnancy:</h2>Teratogenic Effects - <span class="Italics">Pregnancy Category C.</span><br><a href="#section-8.6"></a><span class="Bold">Codeine:</span><br>A study in rats and rabbits reported no teratogenic effect of 
codeine administered during the period of organogenesis in doses ranging from 5 
to 120 mg/kg. In the rat, doses at the 120-mg/kg level, in the toxic range for 
the adult animal, were associated with an increase in embryo resorption at the 
time of implantation. In another study a single 100-mg/kg dose of codeine 
administered to pregnant mice reportedly resulted in delayed ossification in the 
offspring.<p class="First">There are no studies in humans, and the significance of these findings to 
humans, if any, is not known.</p>
<a href="#section-8.6"></a><a href="#section-8.6"></a><span class="Bold">Promethazine:</span><br>Teratogenic effects have not been demonstrated in rat-feeding 
studies at doses of 6.25 and 12.5 mg/kg of promethazine HCl. These doses are 
from approximately 2.1 to 4.2 times the maximum recommended total daily dose of 
promethazine for a 50-kg subject, depending upon the indication for which the 
drug is prescribed. Daily doses of 25 mg/kg intraperitoneally have been found to 
produce fetal mortality in rats.<p>Specific studies to test the action of the drug on parturition, lactation, 
and development of the animal neonate were not done, but a general preliminary 
study in rats indicated no effect on these parameters. Although antihistamines 
have been found to produce fetal mortality in rodents, the pharmacological 
effects of histamine in the rodent do not parallel those in man. There are no 
adequate and well-controlled studies of promethazine in pregnant women.</p>
<p>Promethazine and codeine should be used during pregnancy only if the 
potential benefit justifies the potential risk to the fetus.</p>
<a href="#section-8.6"></a><a href="#section-8.6"></a>Nonteratogenic Effects -<p><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> has been reported in newborns whose mothers took 
opiates regularly during pregnancy. Withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, 
excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Signs 
usually appear during the first few days of life.</p>
<p>Promethazine administered to a pregnant woman within two weeks of delivery 
may inhibit platelet aggregation in the newborn.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.7"></a><p></p>
<h2>Labor And Delivery:</h2>
<p class="First">Narcotic analgesics cross the placental barrier. The closer to 
delivery and the larger the dose used, the greater the possibility of 
<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn. Narcotic analgesics should be avoided 
during labor if delivery of a premature infant is anticipated. If the mother has 
received narcotic analgesics during labor, newborn infants should be observed 
closely for signs of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Resuscitation may be required <span class="Bold">(see OVERDOSAGE).</span></p>
<p>Limited data suggest that use of promethazine hydrochloride during labor and 
delivery does not have an appreciable effect on the duration of labor or 
delivery and does not increase the risk of need for intervention in the 
newborn.</p>
<p>The effect of promethazine and/or codeine on the later growth and development 
of the newborn is unknown.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether promethazine is excreted in human 
milk.</p>
<p>Codeine is secreted into human milk. In women with normal codeine metabolism 
(normal CYP2D6 activity), the amount of codeine secreted into human milk is low 
and dose-dependent. Despite the common use of codeine products to manage 
postpartum <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reports of adverse events in infants are rare. However, some 
women are ultra-rapid metabolizers of codeine. These women achieve 
higher-than-expected serum levels of codeine's active metabolite, morphine, 
leading to higher-than-expected levels of morphine in breast milk and 
potentially dangerously high serum morphine levels in their breastfed infants. 
Therefore, maternal use of codeine can potentially lead to serious adverse 
reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, in nursing infants.</p>
<p>The prevalence of this CYP2D6 phenotype varies widely and has been estimated 
at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1–10% in 
Caucasians, 3% in African Americans, and 16–28% in North Africans, Ethiopians 
and Arabs. Data is not available for other ethnic groups.</p>
<p>The risk of infant exposure to codeine and morphine through breast milk 
should be weighed against the benefits of breastfeeding for both the mother and 
baby. Caution should be exercised when codeine is administered to a nursing 
woman. If a codeine-containing product is selected, the lowest dose should be 
prescribed for the shortest period of time to achieve the desired clinical 
effect. Mothers using codeine should be informed about when to seek immediate 
medical care and how to identify the signs and symptoms of neonatal toxicity, 
such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, difficulty breastfeeding, breathing 
difficulties, and decreased tone, in their baby. Nursing mothers who are 
ultra-rapid metabolizers may also experience <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> symptoms such as extreme 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>. Prescribers should closely monitor 
mother-infant pairs and notify treating pediatricians about the use of codeine 
during breastfeeding <span class="Bold">(see PRECAUTIONS 
– General - Ultra-Rapid 
Metabolizers</span><span class="Bold"> of Codeine).</span></p>
<p>Caution should be exercised when promethazine with codeine syrup is 
administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.9"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride 
and codeine phosphate is contraindicated in pediatric patients less than 6 years 
of age, because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this 
age population</span><span class="Bold"><span class="Bold"></span>(see WARNINGS 
– Box Warning and Use 
In Pediatric Patients).</span><span class="Bold"></span></p>
<p>The combination of promethazine hydrochloride and codeine phosphate should be 
used with caution in pediatric patients 6 years and older <span class="Bold">(see Warnings-Use 
in Pediatric Patients)</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6.10"></a><p></p>
<h2>Geriatric Use:</h2>
<p class="First">Clinical studies of promethazine hydrochloride and codeine 
phosphate syrup did not include sufficient numbers of subjects aged 65 and over 
to determine whether they respond differently from younger subjects. Other 
reported clinical experience has not identified differences in responses between 
the elderly and younger patients. In general, dose selection for an elderly 
patient should be cautious, usually starting at the low end of the dosing range, 
reflecting the greater frequency of decreased hepatic, renal or cardiac 
function, and of concomitant disease or other drug therapy.</p>
<p>Sedating drugs may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and over-sedation in the elderly; elderly 
patients generally should be started on low doses of promethazine with codeine 
syrup and observed closely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Codeine:</span></p>
<p>Nervous System – <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, particularly <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and to 
a lesser extent circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; light-headedness, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation, 
<span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, transient <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, visual 
disturbances, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Cardiovascular – <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, faintness, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, 
<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (common to narcotic analgesics).</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and biliary tract spasm. 
Patients with chronic <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> may experience increased colonic 
motility; in patients with <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">acute ulcerative colitis</span>, toxic dilation has been 
reported.</p>
<p>Genitourinary – <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; antidiuretic effect has been 
reported (common to narcotic analgesics).</p>
<p>Allergic – Infrequent <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">giant urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, and 
<span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p>Other – <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> of the face, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (due to opiate-induced 
histamine release); <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
<p><span class="Bold">Promethazine:</span></p>
<p>Central Nervous System – <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> is the most prominent CNS effect of this 
drug. Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
<span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> such as <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, 
<span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and tongue protrusion; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, 
<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, convulsive 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, excitation, <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonic</span>-like states, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>. <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have also 
been reported.</p>
<p>Cardiovascular – Increased or decreased blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, 
<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, faintness.</p>
<p>Dermatologic – <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Hematologic – <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, 
<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Gastrointestinal – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p>Respiratory – <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (potentially 
fatal) and <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (potentially fatal). <span class="Bold">(See WARNINGS 
- Promethazine; Respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>.)</span></p>
<p>Other – <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span>. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (potentially 
fatal) has also been reported.<span class="Bold"> (See WARNINGS 
- Promethazine; Neuroleptic 
Malignant Syndrome.)</span></p>
<p>Paradoxical Reactions – <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Hyperexcitability</span> and abnormal movements have been 
reported in patients following a single administration of promethazine HCI. 
Consideration should be given to the discontinuation of promethazine HCl and to 
the use of other drugs if these reactions occur. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, 
<span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> behavior have also been reported in some of 
these patients.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<span class="Bold">Controlled Substance:</span><p class="First">Promethazine with codeine syrup is a Schedule V Controlled 
Substance.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Abuse:</span><p>Codeine is known to be subject to abuse; however, the abuse 
potential of oral codeine appears to be quite low. Even parenteral codeine does 
not appear to offer the psychic effects sought by addicts to the same degree as 
heroin or morphine. However, codeine must be administered only under close 
supervision to patients with a history of drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</span><p>Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance are 
known to occur with codeine</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<span class="Bold">Codeine:</span><p class="First">Serious <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with codeine is characterized by respiratory 
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes 
respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, 
skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The triad of <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, pinpoint pupils, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> is 
strongly suggestive of opiate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. In severe overdosage, particularly by 
the intravenous route, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> 
may occur. Promethazine is additive to the depressant effects of codeine.</p>
<p>It is difficult to determine what constitutes a standard toxic or lethal 
dose. However, the lethal oral dose of codeine in an adult is reported to be in 
the range of 0.5 to 1.0 gram. Infants and children are believed to be relatively 
more sensitive to opiates on a body-weight basis. Elderly patients are also 
comparatively intolerant to opiates.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Promethazine:</span><p>Signs and symptoms of overdosage with promethazine HCl range from 
mild <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system and cardiovascular system to 
profound <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. 
Other reported reactions include <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>, 
and extensor-plantar reflexes (Babinski reflex).</p>
<p>Stimulation may be evident, especially in children and geriatric patients. 
<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may rarely occur. A paradoxical-type reaction has been reported in 
children receiving single doses of 75 mg to 125 mg orally, characterized by 
<span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">hyperexcitability</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>.</p>
<p>Atropine-like signs and symptoms – <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4011326" conceptname="Fixed dilatation of pupil">fixed dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, 
as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> may occur.</p>
<a href="#section-"></a><a href="#section-"></a><span class="Bold">Treatment:</span><p>The treatment of overdosage with promethazine and codeine is 
essentially symptomatic and supportive. Only in cases of extreme overdosage or 
individual sensitivity do vital signs including respiration, pulse, blood 
pressure, temperature, and EKG need to be monitored. Activated charcoal orally 
or by lavage may be given, or sodium or magnesium sulfate orally as a cathartic. 
Attention should be given to the reestablishment of adequate respiratory 
exchange through provision of a patent airway and institution of assisted or 
controlled ventilation. The narcotic antagonist, naloxone hydrochloride, may be 
administered when significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs with promethazine 
and codeine; any depressant effects of promethazine are not reversed with 
naloxone. Diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Avoid analeptics, which 
may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span> and electrolyte losses should be corrected. A 
rise in temperature or pulmonary complications may signal the need for 
institution of antibiotic therapy.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> usually responds to the administration of norepinephrine 
or phenylephrine. <span class="Bold">EPINEPHRINE SHOULD NOT BE USED</span>, since its use in a patient 
with partial adrenergic blockade may further lower the blood pressure.</p>
<p>Limited experience with dialysis indicates that it is not helpful.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">The combination of promethazine hydrochloride 
and codeine phosphate is contraindicated in pediatric patients less than 6 years 
of age, because the combination may cause fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in this 
age population.</span></p>
<p>It is important that promethazine with codeine syrup is measured with an 
accurate measuring device <span class="Bold">(see PRECAUTIONS-Information 
For Patients).</span> A household teaspoon is not an accurate measuring 
device and could lead to overdosage, especially when half a teaspoon is to be 
measured. It is strongly recommended that an accurate measuring device be used. 
A pharmacist can provide an appropriate device and can provide instructions for 
measuring the correct dose.</p>
<p>The average effective dose for adults and children 12 years of age and over 
is: 1 teaspoonful (5 mL) every 4 to 6 hours, not to exceed 30 mL in 24 
hours.</p>
<p>The average effective dose for children 6 years to under 12 years of age is 
1/2 to 1 teaspoonful (2.5 mL to 5 mL) every 4 to 6 hours, not to exceed 30 mL in 
24 hours.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<span class="Bold">Promethazine hydrochloride and Codeine Phosphate Syrup </span>contains promethazine 
hydrochloride 6.25 mg/5 mL,<br>codeine phosphate 10 mg/5 mL and alcohol 7 percent.<br>It is available in the following sizes:<br><span class="Bold">Manufactured by Hi-Tech Pharmacal Co.,Inc. and<br>Repackaged and Distributed by Apotheca Inc</span>.<br>12634-909-02 Bottle of 60 ML (2oz)<br>12634-909-04 Bottle of 120 ML (4oz)<br>12634-909-06 Bottle of 180 ML (6oz)<br>12634-909-08 Bottle of 240 ML (8oz)<br><span class="Bold">Promethazine hydrochloride and Codeine Phosphate Syrup</span> contains promethazine 
hydrochloride 6.25 mg/5 mL,<br>codeine phosphate 10 mg/5 mL and alcohol 7.4 percent.<br><span class="Bold">Manufactured by Mortin Grove Pharmaceuticals, Inc. and<br>Repackaged and Distributed by Apotheca  Inc.<br></span>12634-908-02 Bottle of 60 ML (2oz)<br>12634-908-04 Bottle of 120 ML (4oz)<br>12634-908-06 Bottle of 180 ML (6oz)<br>12634-908-08 Bottle of 240 ML (8oz)<br>A schedule CS-CV controlled drug substance.<br><span class="Bold"></span>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12"></a><p></p>
<h1>STORAGE AND HANDLING </h1>
<p class="First">Store at 20°-25°C (68°-77°F) [see USP Controlled Room 
Temperature].</p>
<p>Dispense in a tight, light-resistant container with a child-resistant closure 
as defined in the USP.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL, PRINCIPAL DISPLAY PANEL</h1>
<span class="Bold">12634-909-04 120 ml</span><br>PROMETHAZINE HCI<br>And<br>Codeine Phosphate<br>Syrup, USP<br>Rx Only<br>6.25mg/10mg per 5ml<br>CV<br><div class="Figure"><img alt="image of label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=47d4eb4f-6dd4-44b9-aea1-19c4bfc1d425&amp;name=prohydro-03.jpg"></div>
<br><br><br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE WITH CODEINE  		
					</strong><br><span class="contentTableReg">promethazine with codeine  liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:12634-909(NDC:50383-804)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">6.25 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CODEINE PHOSPHATE</strong> (CODEINE) </td>
<td class="formItem">CODEINE PHOSPHATE</td>
<td class="formItem">10 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PROPIONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER </strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">BERRY (Artificial and natural boysenberry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:12634-909-02</td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:12634-909-04</td>
<td class="formItem">120 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:12634-909-06</td>
<td class="formItem">180 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:12634-909-08</td>
<td class="formItem">240 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040151</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROMETHAZINE WITH CODEINE  		
					</strong><br><span class="contentTableReg">promethazine with codeine  liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:12634-908(NDC:60432-606)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROMETHAZINE HYDROCHLORIDE</strong> (PROMETHAZINE) </td>
<td class="formItem">PROMETHAZINE HYDROCHLORIDE</td>
<td class="formItem">6.25 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CODEINE PHOSPHATE</strong> (CODEINE) </td>
<td class="formItem">CODEINE PHOSPHATE</td>
<td class="formItem">10 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PROPIONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (raspberry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:12634-908-02</td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:12634-908-04</td>
<td class="formItem">120 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:12634-908-06</td>
<td class="formItem">180 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:12634-908-08</td>
<td class="formItem">240 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088875</td>
<td class="formItem">01/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Apotheca, Inc.
							(051457844)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6bd465a1-3575-4d4a-9887-e25835cbd5bc</div>
<div>Set id: 47d4eb4f-6dd4-44b9-aea1-19c4bfc1d425</div>
<div>Version: 1</div>
<div>Effective Time: 20100309</div>
</div>
</div> <div class="DistributorName">Apotheca, Inc.</div></p>
</body></html>
